358 related articles for article (PubMed ID: 30311444)
1. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444 [TBL] [Abstract][Full Text] [Related]
2. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells]. Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734 [TBL] [Abstract][Full Text] [Related]